Kaitlyn R Rouillard1, David B Hill2, Mark H Schoenfisch3. 1. Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Marsico Lung Institute/CF Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Physics and Astronomy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Vast Therapeutics, Durham, NC, USA; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: schoenfisch@unc.edu.
Abstract
BACKGROUND: The combination of antibacterial and mucolytic actions makes nitric oxide (NO) an attractive dual-action cystic fibrosis (CF) therapeutic. The delivery of any therapeutic agent through pathological mucus is difficult, and the use of inhaled NO gas is inherently limited by toxicity concerns. Herein, we directly compare the ability of NO to eradicate infection and decrease mucus viscoelastic moduli as a function of delivery method (i.e., as a gas or water-soluble chitosan donor). METHODS: To compare bactericidal action in tissue, an ex vivo porcine lung model was infected and treated with either gaseous NO or NO-releasing chitosan for 5 h. In vitro Pseudomonas aeruginosa biofilm viability was quantified after NO treatment. Human bronchial epithelial mucus and CF sputum were exposed to NO and their viscoelastic moduli measured with parallel plate macrorheology. RESULTS: Larger NO concentrations were achieved in solution when delivered by chitosan relative to gas exposure. The bactericidal action in tissue of the NO-releasing chitosan was greater compared to NO gas in the infected tissue model. Chitosan delivery also resulted in improved antibiofilm action and reduced biofilm viability (2-log) while gaseous delivery had no impact at an equivalent dose (~0.8 µmol/mL). At equivalent NO doses, mucus and sputum rheology were significantly reduced after treatment with NO-releasing chitosan with NO gas having no significant effect. CONCLUSIONS: Delivery of NO by chitosan allows for larger in-solution concentrations than achievable via direct gas with superior bactericidal and mucolytic action.
BACKGROUND: The combination of antibacterial and mucolytic actions makes nitric oxide (NO) an attractive dual-action cystic fibrosis (CF) therapeutic. The delivery of any therapeutic agent through pathological mucus is difficult, and the use of inhaled NO gas is inherently limited by toxicity concerns. Herein, we directly compare the ability of NO to eradicate infection and decrease mucus viscoelastic moduli as a function of delivery method (i.e., as a gas or water-soluble chitosandonor). METHODS: To compare bactericidal action in tissue, an ex vivo porcine lung model was infected and treated with either gaseous NO or NO-releasing chitosan for 5 h. In vitro Pseudomonas aeruginosa biofilm viability was quantified after NO treatment. Human bronchial epithelial mucus and CF sputum were exposed to NO and their viscoelastic moduli measured with parallel plate macrorheology. RESULTS: Larger NO concentrations were achieved in solution when delivered by chitosan relative to gas exposure. The bactericidal action in tissue of the NO-releasing chitosan was greater compared to NO gas in the infected tissue model. Chitosan delivery also resulted in improved antibiofilm action and reduced biofilm viability (2-log) while gaseous delivery had no impact at an equivalent dose (~0.8 µmol/mL). At equivalent NO doses, mucus and sputum rheology were significantly reduced after treatment with NO-releasing chitosan with NO gas having no significant effect. CONCLUSIONS: Delivery of NO by chitosan allows for larger in-solution concentrations than achievable via direct gas with superior bactericidal and mucolytic action.
Authors: Hirotoshi Matsui; Victoria E Wagner; David B Hill; Ute E Schwab; Troy D Rogers; Brian Button; Russell M Taylor; Richard Superfine; Michael Rubinstein; Barbara H Iglewski; Richard C Boucher Journal: Proc Natl Acad Sci U S A Date: 2006-11-20 Impact factor: 11.205
Authors: Z M Quezado; C Natanson; W Karzai; R L Danner; C A Koev; Y Fitz; D P Dolan; S Richmond; S M Banks; L Wilson; P Q Eichacker Journal: J Appl Physiol (1985) Date: 1998-01
Authors: Benjamin J Staudinger; Jocelyn Fraga Muller; Skarphéðinn Halldórsson; Blaise Boles; Angus Angermeyer; Dao Nguyen; Henry Rosen; Olafur Baldursson; Magnús Gottfreðsson; Guðmundur Hrafn Guðmundsson; Pradeep K Singh Journal: Am J Respir Crit Care Med Date: 2014-04-01 Impact factor: 21.405
Authors: Evan M Hetrick; Jae Ho Shin; Nathan A Stasko; C Bryce Johnson; Daniel A Wespe; Ekhson Holmuhamedov; Mark H Schoenfisch Journal: ACS Nano Date: 2008-02 Impact factor: 15.881
Authors: David B Hill; Robert F Long; William J Kissner; Eyad Atieh; Ian C Garbarine; Matthew R Markovetz; Nicholas C Fontana; Matthew Christy; Mehdi Habibpour; Robert Tarran; M Gregory Forest; Richard C Boucher; Brian Button Journal: Eur Respir J Date: 2018-12-06 Impact factor: 16.671